NCT02092935

A Study of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

A Phase II, Randomized, Double-Blind, Active-Controlled Clinical Study to Investigate the Efficacy and Safety of SMT19969 Compared With Vancomycin for the Treatment of Clostridium Difficile-Associated Diarrhoea (CDAD)

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 100 (actual)
• Sponsor: Summit Therapeutics · Industry
• Sex: All
• Age: 18 Years – 90 Years
• Healthy volunteers: Not accepted

Summary

The purpose of this research study is to evaluate the safety and effectiveness of a new oral antibiotic called SMT19969 in treating C. difficile Infection (CDI).

Conditions

• Clostridium Difficile Infection

Interventions

Type	Name	Description
DRUG	SMT19969
DRUG	Vancomycin

Timeline

• Start date: 2014-04-01
• Primary completion: 2015-10-01
• Completion: 2015-10-01
• First posted: 2014-03-20
• Last updated: 2016-10-20

Locations

26 sites across 2 countries: United States, Canada